 | | Vol. 9.38 – 6 October, 2021 |
| |
|
|
| Scientists showed that induction of the transcription factor CREB1 and its target genes by the recombinant canarypox vector ALVAC + Alum augmented immunogenicity in non-human primates and predicted reduced HIV-1 acquisition in the RV144 trial.
[Nature Immunology] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors identified camelid-derived single domain antibodies that neutralized both SARS-CoV-1 and SARS-CoV-2, including currently circulating variants.
[Science Translational Medicine] |
|
|
|
| Researchers reported canonical and alternative structures including 5′-UTR and 3′-UTR, frameshifting element pseudoknot and genome cyclization in both cells and virions.
[Nature Communications] |
|
|
|
| Using a combination of computational, lipidomics, and biochemical approaches, investigators showed that SARS-CoV-2 lipidation controlled spike biogenesis and degradation, and drove the formation of localized ordered cholesterol and sphingolipid-rich lipid nanodomains in the early Golgi, where viral budding occured.
[Developmental Cell] |
|
|
|
| The authors evaluated endothelial damage via surrogate systemic endothelial biomarkers, that is, proadrenomedullin and proendothelin, in patients with COVID-19.
[Thorax] |
|
|
|
| Human COVID-19+ or vaccinated antibody isotypes, titers, variant RBD binding, and neutralization potential were studied, revealing numerous significant correlations.
[Cell Reports] |
|
|
|
| Investigators determined the frequency, duration, and concentration of nucleocapsid antigen in plasma and its association with COVID-19 severity.
[Clinical Chemistry] |
|
|
|
| The authors developed PRAK-03202, the world’s first triple antigen virus-like particle vaccine candidate, by cloning and transforming SARS-CoV-2 gene segments into a highly characterized S. cerevisiae-based D-Crypt™ platform, which induced SARS CoV-2 specific neutralizing antibodies in BALB/c mice.
[Heliyon] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Scientists identified BstA, a family of prophage-encoded phage-defense proteins in diverse Gram-negative bacteria.
[Cell Host & Microbe] |
|
|
|
| Researchers screened a library of small molecules containing serine-reactive electrophiles and identified narrow-spectrum inhibitors of M. tuberculosis growth.
[Cell Chemical Biology] |
|
|
|
| Investigators studied the effects of 1,2,3-triazole ureas on Mycobacterium tuberculosis. After screening ∼200 compounds, they focused on four compounds that formed a structure-activity series.
[Cell Chemical Biology] |
|
|
|
| Scientists investigated metabolic and functional responses of NK cells to simian adenovirus prime and MVA boost vaccination in a cohort of healthy volunteers receiving a dual HCV-HIV-1 vaccine.
[npj Vaccines] |
|
|
|
|
| The authors provide the structural and cellular foundations for understanding the multistep SARS-CoV-2 entry process.
[Nature Reviews Molecular Cell Biology] |
|
|
|
| Scientists discuss the complex immunological context of cachexia, a systemic catabolic syndrome that depletes both fat and muscle mass with profound consequences for patient prognosis.
[Nature Reviews Immunology] |
|
|
|
| Acid sphingomyelinase cleaves sphingomyelin into the highly lipophilic ceramide, which forms large gel-like rafts/platforms in the plasma membrane. Investigators showed that SARS-CoV-2 uses these platforms for cell entry.
[Molecular Psychiatry] |
|
|
|
|
| SAB Biotherapeutics, Inc. announced that the first patient has been dosed with SAB-185 in the Phase III ACTIV-2 COVID-19 trial.
[SAB Biotherapeutics, Inc.] |
|
|
|
| Pfizer, Inc. announced the start of the Phase II/III EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study to evaluate the investigational novel oral antiviral candidate PF-07321332, co-administered with a low dose of ritonavir, for the prevention of COVID-19 infection.
[Pfizer, Inc.] |
|
|
|
|
| November 6 – 7, 2021
Waterville Valley, New Hampshire, United States |
|
|
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | Colorado State University – Fort Collins, Colorado, United States |
|
|
|
| | Vaccibody AS – Oslo, Norway |
|
|
|
| | Vanderbilt University Medical Center – Nashville, Tennessee, United States |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
